| Budget Amount *help |
¥4,420,000 (Direct Cost: ¥3,400,000、Indirect Cost: ¥1,020,000)
Fiscal Year 2014: ¥2,210,000 (Direct Cost: ¥1,700,000、Indirect Cost: ¥510,000)
Fiscal Year 2013: ¥2,210,000 (Direct Cost: ¥1,700,000、Indirect Cost: ¥510,000)
|
|---|
| Outline of Final Research Achievements |
We developed immune cell therapy using induced pluripotent stem (iPS) cells. In this study, the efficacy of human iPS cell-derived macrophages (iPS-MP) genetically modified to express type I IFNs against human melanoma cells was examined. The iPS-ML expressing type I IFNs increased the expression of CD169, a marker of M1 macrophages that can activate antitumor immunity. The overexpression of type I IFNs in the iPS-ML enhanced the inhibitory effects against the disseminated human melanoma cells in SCID mice.
We also found FOXM1 as a new therapeutic target of melanoma. Furthermore, we identified that hair shaft levels of microRNA-221 could be a non-invasive diagnostic tool for melanoma.
|
